U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
The Swiss biotech was last year reported to be a target of Shire.
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?